Global Health share price
NSE: MEDANTABSE: 543654Healthcare ServicesSmall Cap
Global Health Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Nov 2022 · Issue price ₹336
Last close ₹1,283.00up ₹22.40 (1.78%)BSE ₹1,284.05
Share price at the NSE close on 28 Oct 2026. Previous close ₹1,260.60.
28 Oct: open ₹1,260.60, high ₹1,295.10, low ₹1,243.40
52-week range of traded prices to 28 Oct 2026
₹956.00Low, 30 Mar 2026₹1,544.00High, 27 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹34,497 Cr262nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 62.02
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 8.71
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.04%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 15.1%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.30
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,30,20547.0% delivered
About Global Health
Global Health Limited runs Medanta, a chain of multi-specialty hospitals that provide tertiary and quaternary care, the complex treatment that needs specialist teams and equipment.12 Its hospitals are in Gurugram, Lucknow, Patna, Noida, Indore and Ranchi.3 Outside its hospitals it runs Medanta Clinics, Medanta Labs for diagnostic tests, Medanta Pharmacy and Medanta Homecare.45
Its main specialties are heart, cancer, digestive diseases, neurosciences, kidney and urology, internal medicine, orthopaedics and liver transplant.6 It was incorporated in 2004, the year it acquired a 43-acre site in Gurugram, where its first hospital opened in 2009.78 It opened hospitals in Lucknow in 2019 and in Patna in 2021, the Patna hospital under a public-private partnership (a partnership with the government).89 Its wholly owned subsidiaries include Global Health Patliputra Private Limited and GHL Pharma & Diagnostic Private Limited.10
Its promoter is Naresh Trehan, a cardiac surgeon who founded Medanta and is its chairman and managing director.1112 Sunil Sachdeva, a co-founder, is a non-executive director.13 The Carlyle Group, a minority investor, sold its whole stake when the company listed on BSE and NSE through an initial public offering.14
Global Health key points
Results
- In the quarter to Jun 2026, consolidated total income (revenue plus other income) rose 26.2% to ₹13,262 million, the highest for any quarter, the company says.1516
- EBITDA (earnings before interest, tax, depreciation and amortisation) before employee stock option costs, as the company presents it, was ₹3,153 million in the quarter to Jun 2026, up 23.5%, a margin of 23.8%.17
- Profit after tax in the quarter to Jun 2026 was ₹1,573 million, against ₹1,590 million a year earlier, when profit included one-time income of ₹196 million.16
- In the year to Mar 2026, consolidated total income rose 19.6% to ₹45,089 million, EBITDA before employee stock option costs was ₹10,560 million, a margin of 23.4%, and profit after tax rose 15.1% to ₹5,541 million.18
Market position
Hospital clusters
- Cluster 1, the hospitals in Gurugram, Indore and Ranchi, had revenue of ₹7,715 million in the quarter to Jun 2026, up 10%, and EBITDA of ₹1,858 million, up 13%, a margin of 24.1%.21
- Cluster 2, the hospitals in Lucknow, Patna and Noida, had total income of ₹4,983 million in the quarter to Jun 2026, up 55%, and EBITDA of ₹1,272 million, up 35%.22
- Medanta Noida had total income of ₹855 million in the quarter to Jun 2026, and its EBITDA (before employee stock option costs) loss narrowed to ₹49 million from ₹236 million in the quarter to Mar 2026.23
International patients and OPD pharmacy
- In the quarter to Jun 2026, revenue from international patients rose 23.0% to ₹782 million, and revenue of the outpatient (OPD) pharmacy business, in hospitals and retail stores, rose 50.9% to ₹609 million.24
- In the year to Mar 2026, international patient revenue rose 33.2% to ₹2,780 million, from patients of more than 130 countries, and OPD pharmacy revenue rose 30.4% to ₹1,826 million.25
Hospitals and beds
- Beds by hospital262728The hospitals had 3,737 installed beds in all at the end of June 2026.
Item Jun 2026 Gurugram 1,440 Lucknow 778 Patna 601 Noida 433 Ranchi (2 units) 310 Indore 175 - In the quarter to Jun 2026, inpatients rose 28% and outpatient visits 34% from a year earlier, and network occupancy (the share of beds in use) was 63%. Average revenue per occupied bed (hospital revenue per bed filled for a day) rose 5% to ₹70,244.29
- In the year to Mar 2026, inpatients numbered 202,112, up 16.0%, and outpatient visits numbered 3,485,997.30
Labs, pharmacies and clinics
- Medanta Labs, the retail diagnostics business, had revenue of ₹459 million in the year to Mar 2026, up 39.0%. By June 2026 it had 12 labs and more than 325 collection centres across more than 100 cities.3132
- Medanta Pharmacy had 22 outlets in June 2026: 7 in hospitals, 2 in Medanta Mediclinics and 13 retail pharmacies.32
- In June 2026 the company ran 9 Medanta Clinics in 6 cities, and in the year to Mar 2026 it managed more than 90 neighbourhood clinics with Resident Welfare Associations (residents' groups of housing estates).3331
Expansion and capital spending
- On its earnings call of 31 Jul 2026, the company said its announced expansion pipeline represents nearly 3,350 additional beds, in existing hospitals and at new sites.3435
- New hospitals the company plans, by beds, as of its annual report3637In its presentation of 30 Jul 2026, the company said the Guwahati hospital, enlarged to 650 beds, is to cost ₹9,700 million.
Item Mar 2026 Pitampura, New Delhi 750 Oshiwara, Mumbai 750 Guwahati 650 South Delhi 400 Varanasi 400 - In its presentation of 30 Jul 2026, the company said it plans capital spending of about ₹48,500 million over the next 5 years, funded by debt and internal accruals (cash the business generates).37
- In its presentation of 30 Jul 2026, the company said it is adding an 80-bed cancer hospital in Indore under a business transfer agreement (a deal to take over an existing business), to start operating between July and December 2026.38
Recent events
- On 29 Sep 2026, the company said it had been allotted about 10,560 square metres of land in Ghaziabad for about ₹165.82 crore, with room for a hospital of more than 350 beds, subject to approvals.39
- On 16 Dec 2025, Crisil Ratings upgraded its long-term credit rating (its view of how likely the company is to repay on time) on ₹1,500 crore of bank loan facilities to Crisil AA/Stable from Crisil AA-/Positive.40
- Medanta Noida, a 550-bed hospital, was formally inaugurated on 27 Nov 2025.41
Last updated
All 41 sources, each with its page
- 1. Investor presentation, 30 Jul 2026, page 33
- 2. Annual report, 21 Aug 2026, page 18
- 3. Annual report, 21 Aug 2026, page 26
- 4. Annual report, 21 Aug 2026, page 33
- 5. Annual report, 21 Aug 2026, page 71
- 6. Annual report, 21 Aug 2026, page 43
- 7. Annual report, 21 Aug 2026, page 75
- 8. Annual report, 21 Aug 2026, page 27
- 9. Annual report, 21 Aug 2026, page 28
- 10. Annual report, 21 Aug 2026, page 77
- 11. Annual report, 21 Aug 2026, page 63
- 12. Annual report, 21 Aug 2026, page 5
- 13. Annual report, 21 Aug 2026, page 65
- 14. Annual report, 21 Aug 2026, page 7
- 15. Investor presentation, 30 Jul 2026, page 7
- 16. Earnings call, 31 Jul 2026, page 4
- 17. Investor presentation, 30 Jul 2026, page 7
- 18. Annual report, 21 Aug 2026, page 76
- 19. Annual report, 21 Aug 2026, page 7
- 20. Investor presentation, 30 Jul 2026, page 24
- 21. Earnings call, 31 Jul 2026, page 6
- 22. Earnings call, 31 Jul 2026, page 6
- 23. Investor presentation, 30 Jul 2026, page 6
- 24. Investor presentation, 30 Jul 2026, page 7
- 25. Annual report, 21 Aug 2026, page 11
- 26. Annual report, 21 Aug 2026, page 19
- 27. Investor presentation, 30 Jul 2026, page 25
- 28. Investor presentation, 30 Jul 2026, page 33
- 29. Earnings call, 31 Jul 2026, page 5
- 30. Annual report, 21 Aug 2026, page 76
- 31. Annual report, 21 Aug 2026, page 71
- 32. Investor presentation, 30 Jul 2026, page 9
- 33. Investor presentation, 30 Jul 2026, page 25
- 34. Earnings call, 31 Jul 2026, page 7
- 35. Annual report, 21 Aug 2026, page 9
- 36. Annual report, 21 Aug 2026, page 72
- 37. Investor presentation, 30 Jul 2026, page 20
- 38. Investor presentation, 30 Jul 2026, page 19
- 39. Exchange filing, 29 Sep 2026, page 2
- 40. Exchange filing, 16 Dec 2025, page 1
- 41. Annual report, 21 Aug 2026, page 28
Results
Consolidated; ₹ crore.Global Health quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +21.3%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +4.1%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,304 Crup 12.51%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹157 Crup 11.01%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 12.1%
Revenue by quarter
Peak revenue ₹1,304 Cr, quarter to Jun 2026; lowest ₹931 Cr, quarter to Mar 2025
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 957 | 943 | 931 | 1,031 | 1,099 | 1,121 | 1,159 | 1,304 |
| Net profit | 131 | 143 | 101 | 159 | 158 | 95 | 142 | 157 |
| Net margin | 13.7% | 15.1% | 10.9% | 15.4% | 14.4% | 8.5% | 12.2% | 12.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹4,410 Crup 19.44%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹554 Crup 15.11%
- Net margin
- 12.6%
Revenue by year
Peak revenue ₹4,410 Cr, year to Mar 2026; lowest ₹2,694 Cr, year to Mar 2023
Net profit by year, a loss in red
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 2,694 | 3,275 | 3,692 | 4,410 |
| Net profit | 326 | 478 | 481 | 554 |
| Net margin | 12.1% | 14.6% | 13.0% | 12.6% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Healthcare services, which carries all its revenue.
Valuation
Today, against the company's own history.Global Health PE ratio and valuation
Price to earnings
At or below today's level on 45% of 727 trading days since Nov 2023.
LowestHighest
Its median63.02Industry median42.88
Price to book
At or below today's level on 20% of 744 trading days over the last 3 years.
LowestHighest
Its median9.81Industry median4.47
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 83% of 979 trading days since Nov 2022.
LowestHighest
Its median0.00%Industry median0.25%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −19.7% | +15.6% | −30.6% | 0.1% |
| 3 years | +22.2% | +19.4% | +2.3% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count. Earnings growth over 1 year includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the year to Mar 2025.
Mutual fund holdings
149 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 64 of the 95 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 3 more funds filed their first portfolio on record, holding it.All 149 funds holding Global Health
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 2
- AddedAdded. Funds that held more shares than at the end of the month before.
- 74
- CutCut. Funds that held fewer shares than at the end of the month before.
- 21
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 45
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 4
| Fund | |||
|---|---|---|---|
 Kotak Mid Cap FundKotak Mahindra Mutual Fund | 88,83,314 | 1.82% | ₹1,212.6 Cr |
 Invesco India Mid Cap FundInvesco Mutual Fund | 45,77,395 | 3.97% | ₹624.8 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 32,87,867 | 2.00% | ₹448.8 Cr |
| Invesco India Small Cap FundInvesco Mutual Fund | 21,94,163 | 1.86% | ₹299.5 Cr |
| Invesco India Contra FundInvesco Mutual Fund | 21,02,004 | 1.49% | ₹286.9 Cr |
| Invesco India Focused FundInvesco Mutual Fund | 17,12,376 | 3.75% | ₹233.7 Cr |
| Invesco India Large & Mid Cap FundInvesco Mutual Fund | 17,04,265 | 1.91% | ₹232.6 Cr |
 Canara Robeco Small Cap FundCanara Robeco Mutual Fund | 17,01,593 | 1.66% | ₹232.3 Cr |
| Canara Robeco Large and Mid Cap FundCanara Robeco Mutual Fund | 15,22,049 | 0.85% | ₹207.8 Cr |
 HDFC Multi Cap FundHDFC Mutual Fund | 11,25,000 | 0.79% | ₹153.6 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 28 Oct 2025.Global Health insider trading
No promoter, director, key manager or employee bought or sold on the market.
- Others: no market trade · 9 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Global Health competitors and peers
Hospital, 40 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Global Health in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Max Healthcare InstituteMAXHEALTH | 82,877 | 56.87 | 7.71 | +16.0% | +27.0% | 14.5% | 13.0% | 0.23% |
 Aster DM Quality CareASTERDM | 58,354 | 183.11 | – | +15.7% | +0.2% | 8.0% | 12.4% | 0.45% |
 Fortis HealthcareFORTIS | 57,339 | 54.72 | 5.79 | +17.5% | +20.7% | 11.1% | 12.7% | 0.13% |
 Narayana HrudayalayaNH | 35,213 | 43.15 | 7.76 | +57.8% | +3.9% | 20.0% | 13.1% | 0.26% |
 Krishna Institute of Medical SciencesKIMS | 29,594 | 144.71 | 13.17 | +30.9% | −46.2% | 9.3% | 8.7% | 0.00% |
 Dr. Agarwal's Health CareAGARWALEYE | 15,063 | 101.53 | 7.44 | – | – | 7.6% | 14.1% | 0.00% |
 Rainbow Childrens MedicareRAINBOW | 12,237 | 42.88 | 7.42 | +18.3% | +10.9% | 18.3% | 25.0% | 0.29% |
 Park Medi WorldPARKHOSPS | 9,803 | – | 4.85 | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Global Health dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.50 a share, years to Mar 2025 and Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 14 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.50 |
| 22 Aug 2025 | Final | ₹0.50 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Global Health announcements
Oct 2026
27 Oct · Analysts
23 Oct · Disclosure
22 Oct · Board meeting
Sep 2026
28 Sep · General Updates
Global Health share price by year
Each calendar year to 2025.Global Health share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 1,186.40 | +10.0% | 1,427.20 | 1,001.60 |
| 2024 | 1,078.50 | +12.4% | 1,487.05 | 944.55 |
| 2023 | 959.15 | +104.6% | 1,003.50 | 430.40 |
| 2022 | 468.80 | – | 471.30 | 414.15 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2022 is from its first session, 16 Nov 2022.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 1,212.00 | 1,272.90 | 1,205.10 | 1,260.60 | 1,255.08 | 1,43,451 | 56.4% |
| 26 Oct 2026 | 1,178.00 | 1,232.10 | 1,170.00 | 1,212.00 | 1,200.57 | 78,702 | 35.2% |
| 23 Oct 2026 | 1,192.00 | 1,201.10 | 1,165.00 | 1,185.00 | 1,174.81 | 2,57,718 | 64.6% |
| 22 Oct 2026 | 1,231.90 | 1,231.90 | 1,192.10 | 1,198.20 | 1,206.14 | 5,24,295 | 82.7% |
| 21 Oct 2026 | 1,244.00 | 1,244.00 | 1,213.10 | 1,232.40 | 1,226.12 | 1,39,297 | 58.1% |
| 19 Oct 2026 | 1,240.80 | 1,252.60 | 1,230.00 | 1,238.10 | 1,242.17 | 1,14,325 | 59.0% |
| 16 Oct 2026 | 1,281.00 | 1,290.80 | 1,230.50 | 1,240.00 | 1,259.71 | 3,02,997 | 69.3% |
| 15 Oct 2026 | 1,286.40 | 1,303.20 | 1,267.30 | 1,275.50 | 1,289.96 | 1,51,058 | 49.0% |
| 14 Oct 2026 | 1,286.00 | 1,287.70 | 1,257.50 | 1,280.00 | 1,272.08 | 1,19,827 | 49.6% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- MEDANTA
- BSE code
- 543654
- ISIN
- INE474Q01031
- Industry
- Healthcare Services
- Website
- www.medanta.org
- CIN
- L85110DL2004PLC128319
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2004
- Registered office
- E-18, Medanta - Mediclinic, Defence Colony, New Delhi 110024, Delhi
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, BSE SmallCap, Nifty Total Market